Albert Roger1, Alfons Malet2, Victoria Moreno3, Antonio Parra4, Diego Gutiérrez5, Ramón Lleonart6, Francisco Moreno7, Antonio Valero8, Begoña Navarro9, Belén Hinojosa10, José L Justicia11. 1. Allergy Department, Hospital Germans Trias i Pujol, Badalona, Spain. 2. Al·lergo Centre, Barcelona, Spain. 3. Centro de Especialidades Médicas Integradas, Huelva, Spain. 4. Allergy Department, Hospital A Coruña, A Coruña, Spain. 5. Clínica Virgen del Rosario, Algeciras, Spain. 6. Allergy Department, Hospital Universitari de Bellvitge, Barcelona, Spain. 7. Clínica Dr. Lobatón, Cádiz, Spain. 8. Pneumology and Respiratory Allergy, Hospital Clínic de Barcelona, IDIBAPS, CIBERES, Barcelona, Spain. 9. Allergy Department, Hospital Universitari Dexeus, Barcelona, Spain. 10. Allergy Section, Hospital Juan Ramón Jiménez, Huelva, Spain. 11. Allergy Therapeutics Ibérica, Sant Joan Despí, Barcelona, Spain.
Abstract
Aim: Evaluate the effectiveness and safety of immunotherapy with Acarovac Plus® in a 1-year prospective multicentered real-life study. Methods: A total of 118 adults with allergic rhinitis sensitized to Dermatophagoides received subcutaneous immunotherapy with Acarovac Plus. Treatment outcomes were evaluated at baseline, 6 months and 1 year after treatment initiation. Primary end point was the evolution of the combined symptom and medication score. Secondary end points included other effectiveness outcomes and measurement of product tolerability. Results: Acarovac Plus induced significant improvements in primary and secondary end points after 6 months compared with baseline. These differences persisted after 1 year of treatment (p < 0.001; baseline vs 1 year): combined symptom and medication score (1.60 vs 0.79). No serious adverse events were recorded. Conclusion: Acarovac Plus for 1 year was effective and well tolerated in a real-life setting.
Aim: Evaluate the effectiveness and safety of immunotherapy with Acarovac Plus® in a 1-year prospective multicentered real-life study. Methods: A total of 118 adults with allergic rhinitis sensitized to Dermatophagoides received subcutaneous immunotherapy with Acarovac Plus. Treatment outcomes were evaluated at baseline, 6 months and 1 year after treatment initiation. Primary end point was the evolution of the combined symptom and medication score. Secondary end points included other effectiveness outcomes and measurement of product tolerability. Results:Acarovac Plus induced significant improvements in primary and secondary end points after 6 months compared with baseline. These differences persisted after 1 year of treatment (p < 0.001; baseline vs 1 year): combined symptom and medication score (1.60 vs 0.79). No serious adverse events were recorded. Conclusion:Acarovac Plus for 1 year was effective and well tolerated in a real-life setting.
Authors: Clara Padró; Diego Gutiérrez; Francisco Moreno; Antonio Parra; Manuel J Rial; Ramón Lleonart; Carla Torán-Barona; José L Justicia; Albert Roger Journal: Immun Inflamm Dis Date: 2022-05
Authors: Catalina Gómez; Judit Barrena; Vanesa García-Paz; Ana M Plaza; Paula Crespo; José A Bejarano; Ana B Rodríguez; Laia Ferré; Lidia Farrarons; Marta Viñas; Carla Torán-Barona; Andrea Pereiro; José L Justicia; Santiago Nevot Journal: Eur J Pediatr Date: 2021-12-21 Impact factor: 3.183
Authors: José L Justicia; Clara Padró; Albert Roger; Francisco Moreno; Manuel J Rial; Antonio Parra; Antonio Valero; Alfons Malet; Aina Teniente; Anna Boronat; Carla Torán-Barona Journal: World Allergy Organ J Date: 2021-06-06 Impact factor: 4.084
Authors: Gandhi F Pavón-Romero; Maria Itzel Parra-Vargas; Fernando Ramírez-Jiménez; Esmeralda Melgoza-Ruiz; Nancy H Serrano-Pérez; Luis M Teran Journal: Cells Date: 2022-01-08 Impact factor: 6.600